Remdesivir Completed Phase 3 Trials for Coronavirus Disease 2019 (COVID‑19) Treatment

IndicationsStatusPurposePhase
CompletedTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT04593940Immune Modulators for Treating COVID-19
NCT04492475Adaptive COVID-19 Treatment Trial 3 (ACTT-3)
NCT04401579Adaptive COVID-19 Treatment Trial 2 (ACTT-2)
NCT04280705Adaptive COVID-19 Treatment Trial (ACTT)
NCT04640168Adaptive COVID-19 Treatment Trial 4 (ACTT-4)
NCT05185284Randomized Multicenter Study on the Efficacy and Safety of Favipiravir for Parenteral Administration Compared to Standard of Care in Hospitalized Patients With COVID-19
NCT04853901Remdesivir Efficacy In Management Of COVID-19 Patients
NCT04292730Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment
NCT04292899Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)